Identification and Experimental Validation of Triosephosphate Isomerase 1 as a Functional Biomarker of SHetA2 Sensitivity in Ovarian Cancer
Cells · 2026
DOI: 10.3390/cells15030267 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cells, 2026. Verfasst von Laura F Mortan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Gynecologic Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Ovarian Neoplasms, Triose-Phosphate Isomerase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United States Department of Defense, NCI NIH HHS, National Cancer Institute Cancer Center Support.
Abstract (Originalsprache)
Background
Our objective was to identify and validate proteins that predict which patients with ovarian cancer will respond to SHetA2, an investigational drug in a phase 1 trial for patients with advanced or recurrent solid tumors (clinicaltrials.gov: NCT04928508).
Methods
Cells were cultured from ascites from nine consented patients under an institutional review board-approved protocol. SHetA2 or olaparib sensitivities were determined using metabolic viability assays in ascites-derived cultures or ovarian cancer cell lines. Expression of four SHetA2 target proteins and sixteen proteins previously identified in an ovarian cancer mouse model were measured using microcapillary electrophoresis. Triosephosphate isomerase 1 (TPI1) was modulated by siRNA or lentivirus vector-mediated overexpression. Metabolites were measured using mass spectrometry.
Results
TPI1 was elevated in SHetA2-sensitive compared to SHetA2-resistant ascites-derived cultures (two-way ANOVA q-value = 0.0003). The majority of (5/9) cultures were olaparib-resistant and SHetA2-sensitive. TPI1 was higher in olaparib-resistant cultures (two-way ANOVA q-value = 0.0003). Reduction in or overexpression of TPI1 reduced or increased SHetA2 potency, respectively, in two ovarian cancer cell lines (t-tests; p < 0.05). SHetA2 reduced the metabolites in glycolysis downstream of TPI1, the tricarboxylic acid cycle and oxidative pentose phosphate pathway.
Conclusions
TPI1 is a candidate functional biomarker of SHetA2 sensitivity in ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gynecologic Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA.
- Pathology Department, University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA.
- Obstetrics and Gynecology Department, College of Medicine, University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA.
ORCID-Profile: Laura F Mortan, Zitha Redempta Isingizwe, Doris Mangiaracina Benbrook
Förderung
- United States Department of Defense
- NCI NIH HHS
- National Cancer Institute Cancer Center Support
Zitieren
APA
Mortan, L. F., Isingizwe, Z. R., & Benbrook, D. M. (2026). Identification and Experimental Validation of Triosephosphate Isomerase 1 as a Functional Biomarker of SHetA2 Sensitivity in Ovarian Cancer. Cells. https://doi.org/10.3390/cells15030267
Vancouver
Mortan LF, Isingizwe ZR, Benbrook DM. Identification and Experimental Validation of Triosephosphate Isomerase 1 as a Functional Biomarker of SHetA2 Sensitivity in Ovarian Cancer. Cells. 2026. doi:10.3390/cells15030267
BibTeX
@article{Mortan2026,
author = {Mortan, Laura F and Isingizwe, Zitha Redempta and Benbrook, Doris Mangiaracina},
title = {Identification and Experimental Validation of Triosephosphate Isomerase 1 as a Functional Biomarker of SHetA2 Sensitivity in Ovarian Cancer},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15030267}
}
EUVIMED